Results 211 to 220 of about 276,897 (341)

Best Practice PD-L1 Staining and Interpretation in Gastric Cancer Using PD-L1 IHC PharmDx 22C3 and PD-L1 IHC PharmDx 28-8 Assays, with Reference to Common Issues and Solutions. [PDF]

Biomedicines
Ahn S, Hwang I, Kim Y, Lee S, Cho Y, Kang SY, Kim DG, Lee J, Kim KM.   +8 more
europepmc   +1 more source

Supplemental Table 2 from Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors

, 2023
Matthew D. Hellmann, Nicoletta Bivi, Boris Calderón, Toshio Shimizu, Brant Delafontaine, Zhuqing Tina Liu, Anna M. Szpurka, Victoria Copeland, F. Stephen Hodi, Sylvie Rottey, Philippe Aftimos, Yongzhe Piao, Leena Gandhi, Violeta Régnier Galvão, Ching Ching Leow, Toshihiko Doi   +15 more
openalex   +1 more source

Targeting the Notch1‐YY1‐ICAM1 Signaling Axis Enhances the Efficacy of Immunotherapy in HCC by Activating CD8+ T‐Cell‐Driven Cancer Cell Pyroptosis

Advanced Science, EarlyView.
In hepatocellular carcinoma (HCC), aberrantly activated Notch1 signaling induces its target gene YY1, which impairs immunotherapy efficacy by suppressing tumor cell‐ICAM1‐driven T cell activation and the mediated pyroptosis of T cells against tumor cells.
Ke Zhu, Fa‐Peng Zhang, Chao Qin, Zhi‐Xiao Song, Cai‐Ni Yang, Shu‐Sheng Lin, Xian‐Huan Yu, Wen‐Rui Wu, Chao‐Qun Liu, Chao Liu, Lei‐Bo Xu   +10 more
wiley   +1 more source

Targeting PD-L1-CMTM6 interactions in myeloid cells triggers PD-L1 degradation and enhances cytotoxic T-cell expansion. [PDF]

J Immunother Cancer
Hsu MA, Liu X, Barham W, Pavelko KD, Harrington SM, Lin C, Hirdler JB, Mao Z, Zhang W, Dellacecca ER, Ashton DS, Sun ND, Lancaster JN, Lucien F, Dong H.   +14 more
europepmc   +1 more source

Human cytomegalovirus UL23 exploits PD-L1 inhibitory signaling pathway to evade T cell-mediated cytotoxicity

琴二 栗原, Zhaosong Fan, Wenqiang Huang, Xiaoping Huo, Xiaoping Yang, Yanhong Ran, Jun Chen, Hongjian Li   +7 more
openalex   +1 more source

Supplementary Data from Myeloid Cell–associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing

, 2023
Li Wang, John P. Sfakianos, Kristin G. Beaumont, Güray Aktürk, Amir Horowitz, Robert Sebra, Adam M. Farkas, Sacha Gnjatic, Austin Hake, Sudeh Izadmehr, Peter Wiklund, William Oh, Péter M. Szabó, Megan Wind‐Rotolo, Keziban Ünsal-Kaçmaz, Xin Yao, Eric E. Schadt, Padmanee Sharma, Nina Bhardwaj, Jun Zhu, Matthew D. Galsky   +20 more
openalex   +1 more source

Stress‐Programmed Immune Niches Fuel TNFR2+ Treg Activation and Drive Neoadjuvant Chemotherapy Resistance in Breast Cancer

Advanced Science, EarlyView.
Single‐cell sequencing reveals stress‐programmed immune states driving TNFα–TNFR2–mediated Treg activation and therapy resistance in breast cancer, while targeting this axis restores antitumor immunity. ABSTRACT The tumor microenvironment (TME) harbors diverse immune cell states that shape therapeutic outcomes in breast cancer.
Zhibo Shao, Xuliren Wang, Han Zhu, Ling Yao, Qi Zhang, Zihan Zhai, Xinyi Lv, Xinyuan Xia, Yi Zhang, Xinya Lu, Xinyi Quan, Jiawen Yang, Xinwei Li, Jieyi Dong, Zhi‐ming Shao, Ruoxi Wang, Bingqiu Xiu, Jiong Wu, Sheng Chen   +18 more
wiley   +1 more source

Expression and role of PD-L1 and SOX10 in hepatocellular carcinoma. [PDF]

Transl Cancer Res
So BC, Park HJ, Kim KM, Park HS, Jang KY, Chung MJ, Moon WS, Yang JD, Ahn AR.   +8 more
europepmc   +1 more source

Data from Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data

, 2023
Alexios Matikas, Ioannis Zerdes, John Lövrot, François Richard, Christos Sotiriou, Jonas Bergh, Antonios Valachis, Theodoros Foukakis   +7 more
openalex   +1 more source

TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy

Advanced Science, EarlyView.
We developed TriCON, a triple‐modality nanotherapeutic platform, to treat pancreatic ductal adenocarcinoma (PDAC) by synergizing gene editing, chemotherapy, and immunotherapy. TriCON utilizes CRISPR/Cas9 to target the poliovirus receptor (PVR), combined with nano‐encapsulated doxorubicin and checkpoint blockade. This approach achieved significant tumor
Xinyu Peng, Jiaxing Huang, Shengnan Lv, Jian Zhang, Liangliang Zhang, Huan Liu, Yan Liu, Zhen‐An Qiao, Feng Wei, Bao‐Lian Su   +9 more
wiley   +1 more source